Therefore, the discovery of RSK-specific inhibitors will definitely help to advance the knowledge of RSK-mediated mechanisms in lung cancer and to test the potential of these inhibitors in pre-clinical studies. The gene discussed is RPS6KA3; the disease is lung carcinoma.